In another study in patients with advanced melanoma who had progressed on anti-PDL-1/L1 antibodies received combination pembrolizumab plus ipilimumab followed by Pembrolizumab monotherapy, treatment related adverse events occurred in 62 of 70 patients with grade 3–4 occurring in 19 of 70 patients (27%) (Olson et al. 2021). This evidence concerns the gene CD274 and melanoma.